Product Information
BREZTRI AEROSPHERE 160-9-4.8 MCG is a brand product labeled by AstraZeneca Pharmaceuticals LP, priced at $61.5248 per GM under NDC 00310461639. Its NADAC has been published 290 times since Mar 17, 2021.
FDA first approved this application on Jul 23, 2020.
Strength
160; 4.8; 9 ug/1; ug/1; ug/1
Manufacturer
AstraZeneca Pharmaceuticals LPNDC
00310461639
Classification
Brand
Dosage Form
AEROSOL, METERED
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
BUDESONIDE; FORMOTEROL; GLYCOPYRROLATEApproval Type
New Drug (NDA)
FDA Application
NDA212122FDA Approved
7/23/2020
On Market Since
7/23/2020
Pharmacological Classes
Price Statistics
The NADAC for BREZTRI AEROSPHERE 160-9-4.8 MCG has been published 290 times since Mar 17, 2021, and over the history we have for it it has risen 15.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $61.5248 per GM |
|---|---|
| All-time high | $61.5248 (Sep 30, 2026) |
| All-time low | $53.1936 (Mar 17, 2021) |
| 52-week high | $61.5248 |
| 52-week low | $59.2481 |
| Median price | $56.4336 |
| Average price | $57.1154 |
| Largest weekly change | +3.0% (Jan 14, 2026) |
| Weeks tracked | 290 |
| Tracking since | Mar 17, 2021 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AstraZeneca Pharmaceuticals LP manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
budesonide, glycopyrrolate, and formoterol fumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BREZTRI AEROSPHERE 160-9-4.8 MCG?
The current National Average Drug Acquisition Cost (NADAC) for BREZTRI AEROSPHERE 160-9-4.8 MCG, manufactured by AstraZeneca Pharmaceuticals LP, is $61.5248 per GM (NDC 00310461639), effective Sep 30, 2026.
How has the price of BREZTRI AEROSPHERE 160-9-4.8 MCG changed over time?
Over the history we have for it, the NADAC for BREZTRI AEROSPHERE 160-9-4.8 MCG has risen 15.7%. It has been tracked across 290 weekly CMS publications since Mar 17, 2021.
What are the highest and lowest recorded NADAC prices for BREZTRI AEROSPHERE 160-9-4.8 MCG?
Since Mar 17, 2021, the NADAC for BREZTRI AEROSPHERE 160-9-4.8 MCG has ranged from a low of $53.1936 (Mar 17, 2021) to a high of $61.5248 (Sep 30, 2026), with a median of $56.4336 per GM.
Are there cheaper alternatives to BREZTRI AEROSPHERE 160-9-4.8 MCG?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BREZTRI AEROSPHERE 160-9-4.8 MCG, is $61.3039 per GM — about 0% below BREZTRI AEROSPHERE 160-9-4.8 MCG.
Who manufactures BREZTRI AEROSPHERE 160-9-4.8 MCG?
BREZTRI AEROSPHERE 160-9-4.8 MCG (NDC 00310461639) is labeled by AstraZeneca Pharmaceuticals LP, and CMS classifies it as a brand product.